Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NEU-001
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Investissement Québec
Deal Size : $2.9 million
Deal Type : Financing
Neurenati Concludes $1.7 Million Seed Financing with Support from Impulsion PME
Details : The proceeds will be used to effectively advance NEU-001 toward clinical trials. NEU-001 is a proposed first-in-class therapy to treat Hirschsprung's disease, a rare gastrointestinal disease.
Brand Name : NEU-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 18, 2024
Lead Product(s) : NEU-001
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Investissement Québec
Deal Size : $2.9 million
Deal Type : Financing
Lead Product(s) : NEU-001
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Genson Capital
Deal Size : $1.2 million
Deal Type : Funding
Neurenati Completes $1.2 Million Seed Financing for NEU-001 in Hirschsprung Disease
Details : The funding will accelerate the development of Neurenati's NEU-001, which is being evaluated in the preclinical studies for the treatment of Hirschsprung’s disease.
Brand Name : NEU-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 29, 2024
Lead Product(s) : NEU-001
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Genson Capital
Deal Size : $1.2 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?
Reset All
